Impact of Brain Cancer Care Coordinators on Healthcare Utilisation

By Melike Belenli Gümüş

July 22, 2024

Introduction

The Australian Institute of Health and Welfare reported a significant rise in cancer cases, with glioblastoma multiforme (GBM) accounting for 62% of all central nervous system cancers. GBM poses challenges due to its poor median survival rate of 14-16 months. The standard treatment protocol involves a multidisciplinary approach, emphasising the need for seamless coordination among various medical departments. Despite the existing protocols, the lack of a recognised standard regimen post-progression remains a concern.

Cancer care coordination plays a significant role in enhancing healthcare quality for patients, caregivers, and clinicians. Studies have highlighted the positive impact of patient navigators or cancer care coordinators on access to care, therapy adherence, and overall patient satisfaction. In a recent study, the impact of brain cancer care coordinators (BCCCs) on quantitative outcomes such as health service resource utilisation and survival rates of GBM patients was explored.

Role of Brain Cancer Care Coordinators

BCCCs are specialised nurses who support all patients diagnosed with primary brain cancers. They assist with navigation, symptom management, and emotional support for both patients and carers, providing help both in-person at hospitals and via phone calls. Their primary goal is to ensure that patients receive timely and appropriate care, reducing unnecessary hospital visits and improving overall outcomes.

An analysis was conducted on 187 patients diagnosed with glioblastoma within the Hunter New England Local Health District between 2013 and 2019. Healthcare utilisation and outcomes before and after the implementation of BCCCs were compared. The introduction of BCCCs in 2016 marked a significant change in patient management in terms of emergency department (ED) presentations, hospital admissions and the quality of patients’ lives.

ED Presentations and Hospital Admissions

One of the key findings of the study was the impact of BCCCs on ED presentations and hospital admissions. A noticeable reduction in ED visits, from 401 to 300, was observed after the introduction of BCCCs to the healthcare system. Consequently, the total length of stay in the hospital decreased by 25%. These reductions in healthcare resource utilisation underscore the efficiency and cost-effectiveness of BCCCs in managing GBM patients.

Overall Survival Rates

Hong et al. also examined overall survival rates among patients. Before the introduction of BCCCs, the median overall survival was 12.0 months. After the implementation of BCCCs, the median survival slightly decreased to 11.16 months. Although the difference in survival rates was not statistically significant, the reduction in time spent by patients in hospital and ED can be considered as an improvement in the patients’ quality of life.

Cost-Offset Analysis

The cost-offset analysis compared the investment in BCCCs against the valuation of healthcare resource use differences between the pre and post cohorts. The study found that the introduction of BCCCs led to a reduction in emergency presentations by AUD$1200 and hospital admissions by AUD$5500 per patient, which in turn result in an annual saving of AUD$167 634 in healthcare expenditures. When the cost of hiring the care coordinator was taken into account, the program demonstrates an annual net saving of AUD$4410. This finding supports the economic viability of investing in BCCCs as a means to improve patient care and reduce overall healthcare expenditure.

Figure 1: Costs per patient.

Conclusion

Analysing the data of glioblastoma patients allowed a comprehensive evaluation of the impact of cancer care coordinators as it is a disease with a well-established treatment protocol. BCCCs showed an important role in managing healthcare utilisation and outcomes for patients with glioblastoma. It was demonstrated that the introduction of BCCCs led to a reduction in ED presentations and hospital admissions. Although the impact on overall survival rates was not significant, the cost-offset analysis highlighted the economic benefits of investing in BCCCs.

As healthcare systems continue to evolve, the role of specialised care coordinators will become increasingly important. By providing targeted support and improving care coordination, BCCCs can enhance patient outcomes and reduce healthcare costs. Future research should focus on identifying the factors that influence survival rates and exploring ways to optimise the role of BCCCs in patient care.

Reference url

Recent Posts

oral cancer East Africa
   

Oral Cancer in East Africa: The Need for Early Detection

💡 Did you know that Toombak use is a leading risk factor for oral cancer in East Africa?

A recent scoping review sheds light on the shocking prevalence of oral cancer in the region, emphasising the urgent need for public health interventions and improved early detection strategies. Enhancing awareness around risk factors like Toombak, tobacco, and alcohol for tackling this growing health crisis.

Curious about the key insights and their implications for health economics? Look into the full article to find out more!

#SyenzaNews #HealthEconomics #Oncology #GlobalHealth

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.